secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2024-12-18T23:59:59+00:00
Accession:  0001558370-24-016343
Event type: other_material
Sentiment:  positive
Materiality: 0.78
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus reports positive interim Phase 1 soquelitinib data in atopic dermatitis; $12.7M warrant exercise
--------------------------------------------------------------------------------

- Soquelitinib 100mg BID: mean EASI reduction 55.9% at Day 28 vs 27% placebo; 69.1% at Day 58 vs 19.1% placebo.
- At Day 58, 90% of soquelitinib patients achieved EASI-50, 40% EASI-75, 10% EASI-90 vs 25%, 0%, 0% for placebo.
- No significant safety issues; only Grade 1 nausea (1 patient) and COVID-19 (1 patient) reported.
- Samlyn Capital exercised all warrants for 3,633,978 shares, generating ~$12.7M cash proceeds.
- Initial Cohort 2 data (200mg once daily) in 12 patients consistent with Cohort 1; no treatment-related AEs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000155837024016343/0001558370-24-016343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000155837024016343/crvs-20241218x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-016343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer